(Q34409021)

2 August 2017

Complementation of two mutant p53: implications for loss of heterozygosity in cancer (English)

1 reference

2 August 2017

1 reference

3

Mikhail V Blagosklonny

1 reference

2 August 2017

2

Tito Fojo

1 reference

2 August 2017

1

Zoya N Demidenko

1 reference

PubMed ID

15811347

2 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

2 August 2017

1 reference

2 August 2017

579

1 reference

2 August 2017

2231-2235

1 reference

2 August 2017

10

1 reference

2 August 2017

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

p53 downstream targets and chemosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Dynamics in the p53-Mdm2 ubiquitination pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Human lung cancer and p53: the interplay between mutagenesis and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Transactivation of the EGR1 gene contributes to mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Comparison of the effect of mutant and wild-type p53 on global gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

How p53 binds DNA as a tetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

The role of tetramerization in p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Reactivation of mutant p53: a new strategy for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Induction of apoptosis in HeLa cells by trans-activation-deficient p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.012

10.1016/J.FEBSLET.2005.03.012

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

15811347